Evidence map›Paper›PMID 20833348›Full record

ArticleBest practice & research. Clinical gastroenterology2010

Cost-effectiveness of colorectal cancer screening - an overview.

Iris Lansdorp-Vogelaar, Amy B Knudsen, Hermann Brenner

Abstract read
In one paragraph

Article in Best practice & research. Clinical gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Colorectal cancer screening: Modalities and adherence.World journal of gastroenterology · 2024
    Article
  7. Cost-Consequence Analysis of Colon Cancer Screening among Patients with Long-Standing Ulcerative Colitis: 11 Years' Experience of Saudi Population.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  8. Reevaluating the Evidence for Intensive Postoperative Extracolonic Surveillance for Nonmetastatic Colorectal Cancer.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Iris Lansdorp-VogelaarDepartment of Public Health, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. i.vogelaar@erasmusmc.nl
Amy B Knudsen
Hermann Brenner

Funding

A POPULATION-BASED POLICY MODEL FOR COLORECTAL CANCERU01CA088204 · NCI · UNIVERSITY OF MINNESOTA · PI KUNTZ, KAREN M · 2000 to 2010
$2.4M
Modeling Effective Health Policies for Colorectal CancerU01CA097426 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI ZAUBER, ANN GRAHAM · 2002 to 2010
$2.2M
Coordinating Center for Colorectal MicrosimulationU01CA115953 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI ZAUBER, ANN GRAHAM · 2005 to 2009
$1.1M
NCI NIH HHS U01 CA088204NCI NIH HHS U01-CA-088204NCI NIH HHS U01 CA097426NCI NIH HHS U01-CA-097426NCI NIH HHS U01 CA115953NCI NIH HHS U01-CA-115953
6 · The paper itself

Abstract

There are several modalities available for a colorectal cancer (CRC) screening program. When determining which CRC screening program to implement, the costs of such programs should be considered in comparison to the health benefits they are expected to provide. Cost-effectiveness analysis provides a tool to do this. In this paper we review the evidence on the cost-effectiveness of CRC screening. Published studies universally indicate that when compared with no CRC screening, all screening modalities provide additional years of life at a cost that is deemed acceptable by most industrialized nations. Many recent studies even find CRC screening to be cost-saving. However, when the alternative CRC screening strategies are compared against each other in an incremental cost-effectiveness analysis, no single optimal strategy emerges across the studies. There is consensus that the new technologies of stool DNA testing, computed tomographic colonography and capsule endoscopy are not yet cost-effective compared with the established CRC screening tests.

Indexed as

Capsule EndoscopyColonography, Computed TomographicColonoscopyColorectal NeoplasmsCost-Benefit AnalysisEarly Detection of CancerFecesFemaleHumansMaleMass ScreeningOccult BloodQuality-Adjusted Life YearsSigmoidoscopy

Identifiers

PMID20833348
PMCPMC2939039

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.